Vertex Pharmaceuticals
NICE’s Rejection of Trikafta May Signal Price Dispute with Vertex in the UK
Vertex Pharmaceuticals faces a potential reiteration of history in the United Kingdom, where a recent decision by the National Institute ...
Vertex Gears Up for exa-cel Launch, Acknowledges Vast Opportunity with Cautious Outlook
After a prolonged journey in development, the first CRISPR-based gene editing therapy has recently received approval from an FDA advisory ...
FDA Panel Approves First CRISPR Therapy After Rigorous Safety Evaluations
The FDA advisory committee has expressed satisfaction with the evaluation of potential off-target effects conducted by CRISPR Therapeutics and Vertex ...
CRISPR-Vertex’s gene editing therapy faces FDA committee review
A significant milestone in the pharmaceutical industry is on the horizon as an FDA advisory committee prepares to review the ...
Vertex partners with Septerna to develop GPCR-targeting drugs for rare diseases
Septerna, a biotech company, has secured an additional $47.5 million in funding through a licensing agreement with Vertex, a prominent ...
European Commission Grants Approval for ORKAMBI to Treat Cystic Fibrosis in Children Aged 1 to <2 Years
Source – Vertex Pharmaceuticals On July 5, 2023, Vertex Pharmaceuticals announced that the European Commission has granted approval for the ...
Vertex and Lonza Partner for New Cell Therapy Manufacturing Facility, Creating Job Opportunities
Source – Vertex Pharmaceuticals With promising developments in its experimental cell therapy VX-880 for type I diabetes, Vertex Pharmaceuticals is ...
